First‑Line Management of Depression and Anxiety in Older Adults

1. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)

• SSRIs have been extensively studied in elderly populations and are generally safe for treating comorbid depression and anxiety, although efficacy outcomes are mixed. American Heart Association (2024) endorses this safety profile. 1
• Among SSRIs, sertraline shows a lower risk of QT‑interval prolongation compared with citalopram or escitalopram, making it especially appropriate for older patients with cardiac comorbidities. American Heart Association (2024). 1
• The therapeutic effect of SSRIs may require up to 6 weeks to become fully apparent. 1

2. Medication Selection and Dosing

• Avoid mono‑amine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) in older adults because they are associated with significant cardiovascular adverse events such as hypertension, hypotension, and arrhythmias. American Heart Association (2024). 1
• Citalopram may be used but should not exceed 20 mg per day in patients > 60 years due to QT‑prolongation risk. 3
• Paroxetine and fluoxetine are discouraged in the elderly because of heightened anticholinergic effects (paroxetine) and increased risk of agitation/over‑stimulation (fluoxetine). 3
• Initiate SSRIs at roughly 50 % of the standard adult starting dose to reduce adverse‑drug‑reaction risk; for sertraline, begin with 25 mg daily and titrate gradually. 3
• Prior to starting therapy, evaluate renal and hepatic function and adjust doses as needed. 3

3. Monitoring, Response Assessment, and Treatment Adjustment

• Conduct standardized depression/anxiety assessments at 4 weeks and 8 weeks after initiating therapy to gauge response. 4
• If minimal improvement is observed after 8 weeks despite good adherence, modify the regimen by either switching the antidepressant or adding a structured psychological intervention. 4

4. Duration of Pharmacologic Treatment

• Continue antidepressant therapy for at least 6 months after achieving a clinically significant improvement in a first or second episode of major depression. 5
• Patients with recurrent depressive episodes may require maintenance treatment beyond 6 months to sustain remission. 3

5. Role of Psychotherapy

• Cognitive‑behavioral therapy (CBT) is recommended as a first‑line option for mild‑to‑moderate depression in older adults and can be employed alone or in combination with medication. American College of Physicians (2016). 7

6. Additional Safety Considerations (Pitfalls to Avoid)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be avoided in older adults with cardiovascular disease because of heightened risks of cardiovascular toxicity, renal impairment, and bleeding. American Heart Association (2024). 1

All statements are supported by the cited references and reflect current guideline recommendations for the management of depression and anxiety in the elderly.